Core Viewpoint - Regeneron Pharmaceuticals is positioned for significant growth, with the potential to double investors' returns in the coming years due to its promising pipeline and strong financial performance [2][12]. Company Overview - Regeneron Pharmaceuticals is a leading biotech company known for developing treatments across various disease categories, including eye diseases, cancer, and rare diseases [5]. - The company has a market capitalization of $82 billion and has delivered a 106% gain over the past decade [2]. Financial Performance - In 2025, Regeneron's revenue rose 1% to $14.3 billion, while earnings per share increased by 8% to $41.48 [9]. - The company's lead therapy, Dupixent, generated $17.8 billion in revenue in 2025, with additional significant products including Eylea and Libtayo [5][9]. Product Pipeline - Regeneron has 26 candidates in late-stage trials, with expectations for at least four FDA approvals in the current year [3][8]. - The company is also investigating olatorepatide, a GLP-1 weight loss and diabetes candidate, which could significantly boost revenue if approved [10][11]. Market Potential - Analysts predict that olatorepatide could generate $14.8 billion in annual revenues by 2028, surpassing the company's total revenue from the previous year [11]. - The weight-loss drug sector is projected to grow from $4.2 billion in 2025 to $23.6 billion by 2030, indicating substantial market opportunities for Regeneron [12].